Medicinal use requirement governs exemption for bulk drug classification under excise notification

Exemption for citric acid monohydrate BP under the relevant excise notification depended on more than pharmacopoeial conformity or pharmaceutical capability. The product could fall within the broader class of bulk drugs, medicines or drug-intermediates only if it was shown to be used for diagnosis, treatment, mitigation or prevention of disease, or as an ingredient in a medicinal formulation. Mere potential use was insufficient; actual qualifying end use had to be established by evidence and, where necessary, verified by the authorities before exemption or refund could be granted.

---

---

Issues: (i) Whether citric acid monohydrate BP qualified as a bulk drug, medicine or drug-intermediate for the purpose of exemption under the relevant notification; (ii) Whether actual use of the goods in medicines or medicinal formulations was necessary to earn the exemption.

Issue (i): Whether citric acid monohydrate BP qualified as a bulk drug, medicine or drug-intermediate for the purpose of exemption under the relevant notification.

Analysis: The governing notification granted exemption to bulk drugs, medicines and drug-intermediates falling under Item 68 of the Central Excise Tariff, and defined bulk drugs as chemical, biological or plant products conforming to pharmacopoeial standards and used for diagnosis, treatment, mitigation or prevention of disease, or as an ingredient in a formulation. Citric acid monohydrate BP was treated as a chemical product capable of pharmaceutical use and was held to fall within the class of medicinal and drug-intermediate products contemplated by the notification.

Conclusion: Citric acid monohydrate BP was accepted as a medicine and drug-intermediate capable of qualifying as a bulk drug, subject to satisfaction of the use requirement.

Issue (ii): Whether actual use of the goods in medicines or medicinal formulations was necessary to earn the exemption.

Analysis: The notification was read as conferring exemption only where the product was in fact used for diagnosis, treatment, mitigation or prevention of disease, or used as such or as an ingredient in a medicinal formulation. Mere conformity to pharmacopoeial standard or mere capability of being used in medicines was held insufficient. The Tribunal rejected the broader contention that potential or possible use was enough, and held that end-use had to be established by evidence, including enquiry and verification by the customs authorities where necessary.

Conclusion: Actual use in the prescribed medicinal manner was required, and the denial of exemption by the lower authorities was upheld, while the customs authorities were directed to verify end use and extend the exemption where proved.

Final Conclusion: The exemption claim was not automatically allowable on the basis of the product's character alone; entitlement depended on proof of qualifying use, and the matter required factual verification before refund or exemption could be granted.

Ratio Decidendi: For exemption under the notification, a product falling within the description of a bulk drug must be shown by evidence of actual qualifying use in medicine or medicinal formulation, and capability or pharmacopoeial conformity by itself does not suffice.

---